Evaluation of Liver Damage in Patients With Anorexia Nervosa by Blood Biomarker Analysis

The main goal of the BIocoLlection in Anorexia Nervosa-liver damage evaluation BILAN study the blood biomarkers associated with liver cytolysis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anorexia Nervosa Digestive System Diseases Fatty Liver Feeding and Eating Disorders Fibrosis Liver Cirrhosis Liver Diseases Mental Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

15 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Nantes University Hospital

Nantes, Loire-Atlantique, 44093, France

About this study

Study of the association between blood biomarkers and the presence of hepatic cytolysis, defined by AST and/or ALT above normal.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient over 15 years old
Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Admission to Nantes University Hospital.

Exclusion criteria

Chronic active viral hepatitis
Hemochromatosis
Other genetic, autoimmune.
Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months
Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)
Pregnant, parturient or breast-feeding women, persons deprived of liberty, adults under legal protection or unable to express their consent, persons not affiliated or not beneficiaries of a social security scheme, persons under guardianship or curators

Treatment and study plan

Patients with Anorexia Nervosa

Other

Patients with Anorexia Nervosa hospitalized for malnutrition

Primary outcomes

Identification of new blood biomarkers and hepatic cytolysis

Time frame: Two years

Identify changes in concentration of new blood biomarkers in patients suffering from hepatic cytolysis, defined by aspartate transaminases (AST) and/or alanine transaminases (ALT) above normal values, compared to those with normal enzyme levels.

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Official study title

BILAN: Evaluation of Liver Damage in Patients With Anorexia Nervosa by Blood BIomarker ANaLysis

Acronym: BILAN

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Feb 15, 2024
Registry last updated: Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed